Development of a candidate HLA A*0201 restricted peptide-based vaccine against human cytomegalovirus infection

Blood

Volumn 90, Issue 5, 1997, Pages 1751-1767

  Diamond, Don J ^a   York, Joanne ^a   Sun, Ji Yao ^a   Wright, Christine L ^a   Forman, Stephen J ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HLA ANTIGEN CLASS 2;

ANTIGEN SPECIFICITY; ARTICLE; BONE MARROW TRANSPLANTATION; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; CYTOTOXIC T LYMPHOCYTE; FIBROBLAST; GENE TARGETING; HUMAN; HUMAN CELL; PRIORITY JOURNAL; SEROCONVERSION; VACCINE PRODUCTION; VIRUS EXPRESSION; VIRUS GENE; VIRUS GENOME;

EID: 0030928128     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v90.5.1751     Document Type: Article

References (110)

1. Chee MS, Bankier AT, Beck S, Bohni R, Brown CM, Cerny R, Horsnell T, Hutchison CA III, Kouzarides T, Martignetti JA, Preddie E, Satchwell SC, Tomlinson P, Weston KM, Barrell BG: Analysis of the protein-coding content of the sequence of human cytomegalovirus strain AD169. Curr Top Microbiol Immunol 154:125, 1990
2. Gonczol E, Plotkin S: Progress in vaccine development for prevention of human cytomegalovirus infection. Curr Top Microbiol Immunol 154:255, 1990
3. Zaia JA: The biology of human cytomegalovirus infection after bone marrow transplantation. Int J Cell Cloning 4:135, 1986 (suppl 1)
4. Meyers JD: Management of cytomegalovirus infection. Am J Med 85:102, 1988
5. Hillyer CD, Snydman DR, Berkman EM: The risk of cytomegalovirus infection in solid organ and bone marrow transplant recipients: Transfusion of blood products. Transfusion 30:659, 1990
6. Zaia JA: Epidemiology and pathogenesis of cytomegalovirus disease. Semin Hematol 27:5, 1990 (Discussion 27:28, 1990)
7. Stinski MF: Sequence of protein synthesis in cells infected by human cytomegalovirus: Early and late virus-induced polypeptides. J Virol 26:686, 1978
8. Riddell SR, Rabin M, Geballe AP, Britt WJ, Greenberg PD: Class I MHC-restricted cytotoxic T lymphocyte recognition of cells infected with human cytomegalovirus does not require endogenous viral gene expression. J Immunol 146:2795, 1991
9. Grefte JM, van der Gun BT, Schmolke S, van der Giessen M, van Son WJ, Plachter B, Jahn G, The TH: The lower matrix protein pp65 is the principal viral antigen present in peripheral blood leukocytes during an active cytomegalovirus infection. J Gen Virol 73:2923, 1992
10. McLaughlin-Taylor E, Pande H, Forman SJ, Tanamachi B, Li CR, Zaia JA, Greenberg PD, Riddell SR: Identification of the major late human cytomegalovirus matrix protein pp65 as a target antigen for CD8+ virus-specific cytotoxic T lymphocytes. J Med Virol 43:103, 1994
11. Boppana SB, Britt WJ: Recognition of human cytomegalovirus gene products by HCMV-specific cytotoxic T cells. Virology 222:293, 1996
12. Gilbert MJ, Riddell SR, Li CR, Greenberg PD: Selective interference with class I major histocompatibility complex presentation of the major immediate-early protein following infection with human cytomegalovirus. J Virol 67:3461, 1993
13. Riddell SR, Greenberg PD: Therapeutic reconstitution of human viral immunity by adoptive transfer of cytotoxic T lymphocyte clones. Curr Top Microbiol Immunol 189:9, 1994
14. Riddell SR, Watanabe KS, Goodrich JM, Li CR, Agha ME, Greenberg PD: Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones [see comments]. Science 257:238, 1992
15. Walter EA, Greenberg PD, Gilbert MJ, Finch RJ, Watanabe KS, Thomas ED, Riddell SR: Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med 333:1038, 1995
16. Falk K, Rotzschke O, Deres K, Metzger J, Jung G, Rammensee HG: Identification of naturally processed viral nonapeptides allows their quantification in infected cells and suggests an allele-specific T cell epitope forecast. J Exp Med 174:425, 1991
17. Falk K, Rotzschke O, Stevanovic S, Jung G, Rammensee HG: Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. Nature 351:290, 1991
18. Rammensee HG, Falk K, Rotzschke O: Peptides naturally presented by MHC class I molecules. Annu Rev Immunol 11:213, 1993
19. Hunt DF, Henderson RA, Shabanowitz J, Sakaguchi K, Michel H, Sevilir N, Cox AL, Appella E, Engelhard VH: Characterization of peptides bound to the class I MHC molecule HLA-A2.1 by mass spectrometry [see comments]. Science 255:1261, 1992
20. Crumpacker DB, Alexander J, Cresswell P, Engelhard VH: Role of endogenous peptides in murine allogenic cytotoxic T cell responses assessed using transfectants of the antigen-processing mutant 174×CEM.T2. J Immunol 148:3004, 1992
21. Vitiello A, Ishioka G, Grey HM, Rose R, Farness P, LaFond R, Yuan L, Chisari FV, Furze J, Bartholomeuz R: Development of a lipopeptide-based therapeutic vaccine to treat chronic HBV infection. I. Induction of a primary cytotoxic T lymphocyte response in humans. J Clin Invest 95:341, 1995
22. Schipper R, D'Amaro J, Bakker JT, Bakker J, van Rood JJ, Oudshorn M: HLA gene and haplotype frequencies in bone marrow donors worldwide registries. Hum Immun 52:54, 1997
23. Rickinson AB, Rowe M, Hart IJ, Yao QY, Henderson LE, Rabin H, Epstein MA: T-cell-mediated regression of "spontaneous" and of Epstein-Barr virus-induced B-cell transformation in vitro: studies with cyclosporin A. Cell Immunol 87:646, 1984
24. The Central Data Analysis Committee: Section 6.3 splits combined (five loci), in: The Data Book of the 11th International Histocompatibility Workshop. Yokohama, Japan, 1991, p 807
25. Chakrabarti S, Brechung K, Moss B: Vaccinia virus expression vector: Coexpression of beta-galactosidase provides visual screening of recombinant virus plaques. Mol Cell Biol 5:3403, 1985
26. Kozak M: Point mutations close to the AUG initiator codon affect the efficiency of translation of rat preproinsulin in vivo. Nature 308:241, 1984
27. Elroy-Stein O, Moss B: 1991. Expression of proteins in mammalian cells using vaccinia virus vectors, in Coligan JE, Kruisbeek AM, Margulies DH, Shevach E, Strober W (eds): Current Protocols in Immunology. New York, NY, Greene Publishing, p 16.15.1
28. Mackett M, Smith GL, Moss B: General method for production and selection of infectious vaccinia virus recombinants expressing foreign genes. J Virol 49:857, 1984
29. Borysiewicz LK, Graham S, Hickling JK, Mason PD, Sissons JG: Human cytomegalovirus-specific cytotoxic T cells: Their precursor frequency and stage specificity. Eur J Immunol. 18:269, 1988
30. Theobald M, Biggs J, Dittmer D, Levine A, Sherman LA: Targeting p53 as a general tumor antigen. Proc Natl Acad Sci USA 92:11993, 1995
31. Aruffo A, Seed B: Molecular cloning of two CD7 (T-cell leukemia antigen) cDNAs by a COS cell expression system. EMBO J 6:3313, 1987
32. Buchwalder A, Krangel MS, Hao P, Diamond DJ: Immunochemical and molecular analysis of antigen binding to lipid anchored and soluble forms of an MHC independent human alpha/beta T cell receptor. Mol Immunol 31:857, 1994
33. Espevik T, Nissen-Meyer J: A highly sensitive cell line, WEHI 164 clone 13, for measuring cytotoxic factor/tumor necrosis factor from human monocytes. J Immunol Methods 95:99, 1986
34. Millet I, Ruddle NH: Differential regulation of lymphotoxin (LT), lymphotoxin-beta (LT-beta), and TNF-alpha in murine T cell clones activated through the TCR. J Immunol 152:4336, 1994
35. Fields GB, Noble RL: Solid phase peptide synthesis utilizing 9-fluorenylmethoxycarbonyl amino acids. Int J Pept Protein Res 35:161, 1990
36. Wentworth PA, Celis E, Crimi C, Stitely S, Hale L, Tsai V, Serra HM, Del Guercio MF, Livingston B, Alazard D, et al: In vitro induction of primary, antigen-specific CTL from human peripheral blood mononuclear cells stimulated with synthetic peptides. Mol Immunol 32:603, 1995
37. Bernhard EJ, Le AX, Barbosa JA, Lacy E, Engelhard VH: Cytotoxic T lymphocytes from HLA-A2 transgenic mice specific for HLA-A2 expressed on human cells. J Exp Med 168:1157, 1988
38. Alexander J, Sidney J, Southwood S, Ruppert J, Oseroff C, Maewal A, Snoke K, Serra HM, Kubo RT, Sette A: Development of high potency universal DR-restricted helper epitopes by modification of high affinity DR-blocking peptides. Immunity 1:751, 1994
39. Sette A, Vitiello A, Reherman B, Fowler P, Nayersina R, Kast WM, Melief CJ, Oseroff C, Yuan L, Ruppert J, et al: The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes. J Immunol 153:5586, 1994
40. Yu Z, Liu X, McCarty TM, Diamond DJ, Ellenhorn JDI: The use of transgenic mice to generate high affinity p53 specific cytolytic T cells. J Surg Res 69:337, 1997
41. Li CR, Greenberg PD, Gilbert MJ, Goodrich JM, Riddell SR: Recovery of HLA-restricted cytomegalovirus (CMV)-specific T-cell responses after allogeneic bone marrow transplant: Correlation with CMV disease and effect of ganciclovir prophylaxis. Blood 83:1971, 1994
42. Krausa P, Brywka M 3rd, Savage D, Hui KM, Bunce M, Ngai JL, Teo DL, Ong YW, Barouch D, Allsop CE, et al: Genetic polymorphism within HLA-A*02: Significant allelic variation revealed in different populations. Tissue Ant 45:223, 1995
43. Rivoltini L, Loftus DJ, Barracchini K, Arienti F, Mazzocchi A, Biddison WE, Salgaller ML, Appella E, Parmiani G, Marincola FM: Binding and presentation of peptides derived from melanoma antigens MART-1 and glycoprotein-100 by HLA-A2 subtypes. Implications for peptide-based immunotherapy. J Immunol 156:3882, 1996
44. Hosmalin A, Clerici M, Houghten R, Pendleton CD, Flexner C, Lucey DR, Moss B, Germain RN, Shearer GM, Berzofsky JA: An epitope in human immunodeficiency virus 1 reverse transcriptase recognized by both mouse and human cytotoxic T lymphocytes. Proc Natl Acad Sci USA 87:2344, 1990
45. Johnson RP, Hammond SA, Trocha A, Siliciano RF, Walker BD: Induction of an MHC complex class I-restricted CTL response to a highly conserved region of HIV type 1 in seronegative humans immunized with a candidate HIV-1 vaccine. J Virol 68:3145, 1994
46. Moss B: Vaccinia virus vectors. Biotechnology 20:345, 1992
47. Traversari C, van der Bruggen P, Van den Eynde B, Hainaut P, Lemoine C, Ohta N, Old L, Boon T: Transfection and expression of a gene coding for a human melanoma antigen recognized by autologous cytolytic T lymphocytes. Immunogenetics 35:145, 1992
48. Ruddle NH, Bergman CM, McGrath KM, Lingenheld EG, Grunnet ML, Padula SJ, Clark RB: An antibody to lymphotoxin and tumor necrosis factor prevents transfer of experimental allergic encephalomyelitis. J Exp Med 172:1193, 1990
49. Koller BH, Orr HT: Cloning and complete sequence of an HLA-A2 gene: Analysis of two HLA-A alleles at the nucleotide level. J Immunol 134:2727, 1985
50. Knuth A, Wolfel T, Klehmann E, Boon T, Meyer zum Buschenfelde KH: Cytolytic T-cell clones against an autologous human melanoma: Specificity study and definition of three antigens by immunoselection. Proc Natl Acad Sci USA 86:2804, 1989
51. D'Amaro J, Houbiers JG, Drijfhout JW, Brandt RM, Schipper R, Bavinck JN, Melief CJ, Kast WM: A computer program for predicting possible cytotoxic T lymphocyte epitopes based on HLA class I peptide-binding motifs. Hum Immunol 43:13, 1995
52. van der Burg SH, Ras E, Drijfhout JW, Benckhuijsen WE, Bremers AJ, Melief CJ, Kast WM: An HLA class I peptide-binding assay based on competition for binding to class I molecules on intact human B cells. Identification of conserved HIV-1 polymerase peptides binding to HLA-A*0301. Hum Immunol 44:189, 1995
53. Sette A, Sidney J, Del Guercio MF, Southwood S, Ruppert J, Dahlberg C, Grey HM, Kubo RT: Peptide binding to the most frequent HLA-A class I alleles measured by quantitative molecular binding assays. Mol Immunol 31:813, 1994
54. Del Guercio MF, Sidney J, Hermanson G, Perez C, Grey HM, Kubo RT, Sette A: Binding of a peptide antigen to multiple HLA alleles allows definition of an A2-like supertype. J Immunol 154:685, 1995
55. Kubo RT, Sette A, Grey HM, Appella E, Sakaguchi K, Zhu NZ, Arnott D, Sherman N, Shabanowitz J, Michel H: Definition of specific peptide motifs for four major HLA-A alleles. J Immunol 152:3913, 1994
56. Parkhurst M, Salgaller M, Southwood S, Robbins P, Sette A, Rosenberg SA, Kawakami Y: Improved induction of melanoma-reractive CTL with peptides from the melanoma antigen gp100 modified at HLA A*0201-binding residues. J Immunol 157:2539, 1996
57. Yee C, Gilbert MJ, Riddell SR, Brichard VG, Fefer A, Thompson JA, Boon T, Greenberg PD: Isolation of tyrosinase-specific CD8+ and CD4+ T cell clones from the peripheral blood of melanoma patients following in vitro stimulation with recombinant vaccinia virus. J Immunol 157:4079, 1996
58. Wentworth PA, Vitiello A, Sidney J, Keogh E, Chesnut RW, Grey H, Sette A: Differences and similarities in the A2.1-restricted cytotoxic T cell repertoire in humans and human leukocyte antigen-transgenic mice. Eur J Immunol 26:97, 1996
59. Deres K, Schild H, Wiesmuller KH, Jung G, Rammensee HG: In vivo priming of virus-specific cytotoxic T lymphocytes with synthetic lipopeptide vaccine [see comments]. Nature 342:561, 1989
60. Schild H, Deres K, Wiesmuller KH, Jung G, Rammensee HG: Efficiency of peptides and lipopeptides for in vivo priming of virus-specific cytotoxic T cells. Eur J Immunol 21:2649, 1991
61. Schipper R, van Els CACM, D'Amaro J, Oudshorn M: Minimal phenotype panels; a method for achieving maximum population coverage with a minimum of HLA antigens. Hum Immunol 51:95, 1996
62. Drijfhout JW, Brandt RM, D'Amaro J, Kast WM, Melief CJ: Detailed motifs for peptide binding to HLA-A*0201 derived from large random sets of peptides using a cellular binding assay. Hum Immunol 43:1, 1995
63. Engelhard VH: Structure of peptides associated with MHC class I molecules. Curr Opin Immunol 6:13, 1994
64. Wills MR, Carmichael AJ, Mynard K, Jin X, Weekes MP, Plachter B, Sissons JG: The human CTL response to cytomegalovirus is dominanted by structural protein pp65: Frequency, specificity, and T cell receptor usage of pp65-specific CTL. J Virol 70:7569, 1996
65. Parker KC, Bednarek MA, Coligan JE: Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J Immunol 152:163, 1994
66. Plotkin SA, Starr SE, Friedman HM, Gonczol E, Weibel RE: Protective effects of Towne cytomegalovirus vaccine against low-passage cytomegalovirus administered as a challenge. J Infect Dis 159:860, 1989
67. Plotkin SA, Starr SE, Friedman HM, Brayman K, Harris S, Jackson S, Tustin NB, Grossman R, Dafoe D, Barker C: Effect of Towne live virus vaccine on cytomegalovirus disease after renal transplant. A controlled trial [see comments]. Ann Intern Med 114:525, 1991
68. Cadoz M, Strady A, Meignier B, Taylor J, Tartaglia J, Paoletti E, Plotkin S: Immunisation with canarypox virus expressing rabies glycoprotein [see comments]. Lancet 339:1429, 1992
69. Gilles P, Gonzales-Canali G, Gluckman JC, Riviere Y, Plotkin S, Excler JL: Combination prime-boost approach to HIV vaccination in seronegative individuals using a recombinant canarypox virus expressing MN-gp160 and a MN-BRU-rgp 160 protein boosting (ANRS-VAC01). Int Conf AIDS 9:70, 1993 (abstr WS-70)
70. Keefer MC, Graham BS, McElrath MJ, Matthews TJ, Stablein DM, Corey L, Wright PF, Lawrence D, Fast PE, Weinhold K, Hsieh RH, Chernoff D, Dekker C, Dolin R: Safety and immunogenicity of Env 2-3, a human immunodeficiency virus type 1 candidate vaccine, in combination with a novel adjuvant, MTP-PE/MF59. NIAID AIDS Vaccine Evaluation Group. AIDS Res Hum Retroviruses 12:683, 1996
71. Langenberg AG, Burke RL, Adair SF, Sekulovich R, Tigges M, Dekker CL, Corey L: A recombinant glycoprotein vaccine for herpes simplex virus type 2: Safety and immunogenicity [corrected] [published erratum appears in Ann Intern Med 123:395, 1995]. Ann Intern Med 122:889, 1995
72. Wang JB, Adler SP, Hempfling S, Burke RL, Duliege AM, Starr SE, Plotkin SA: Mucosal antibodies to human cytomegalovirus glycoprotein B occur following both natural infection and immunization with human cytomegalovirus vaccines. J Infect Dis 174:387, 1996
73. Britt W, Fay J, Seals J, Kensil C: Formulation of an immunogenic human cytomegalovirus vaccine: responses in mice. J Infect Dis 171:18, 1995
74. Martins LP, Lau LL, Asano MS, Ahmed R: DNA vaccination against persistent viral infection. J Virol 69:2574, 1995
75. Davis HL, McCluskie MJ, Gerin JL, Purcell RH: DNA vaccine for hepatitis B: Evidence for immunogenicity in chimpanzees and comparison with other vaccines. Proc Natl Acad Sci USA 93:7213, 1996
76. McClements WL, Armstrong ME, Keys RD, Liu MA: Immunization with DNA vaccines encoding glycoprotein D or glycoprotein B, alone or in combination, induces protective immunity in animal models of herpes simplex virus-2 disease. Proc Natl Acad Sci USA 93:11414, 1996
77. Gilbert MJ, Riddell S, Plachter B, Greenberg PD: Cytomegalovirus selectively blocks antigen processing and presentation of its immediate-early gene product. Nature 383:720, 1996
78. Sauzet JP, Deprez B, Martinon F, Guillet JG, Gras-Masse H, Gomard E: Long-lasting anti-viral cytotoxic T lymphocytes induced in vivo with chimeric-multirestricted lipopeptides. Vaccine 13:1339, 1995
79. Schulz M, Zinkernagel RM, Hengartner H: Peptide-induced antiviral protection by cytotoxic T cells. Proc Natl Acad Sci USA 88:991, 1991
80. Kearney ER, Pape KA, Loh DY, Jenkins MK: Visualization of peptide-specific T cell immunity and peripheral tolerance induction in vivo. Immunity 1:327, 1994
81. Powell MF, Cleland JL, Eastman DJ, Lim A, Murthy K, Newman MJ, Nunberg JH, Weissburg RP, Vennari JC, Wrin T, et al: Immunogenicity and HIV-1 virus neutralization of MN recombinant glycoprotein 120/HIV-1 QS21 vaccine in baboons [published erratum appears in AIDS Res Hum Retroviruses 11:661, 1995]. AIDS Res Hum Retroviruses 10:S105, 1994 (suppl 2)
82. Babu JS, Nair S, Kanda P, Rouse BT: Priming for virus-specific CD8+ but not CD4+ cytotoxic T lymphocytes with synthetic lipopeptide is influenced by acylation units and liposome encapsulation. Vaccine 13:1669, 1995
83. Schild H, Norda M, Deres K, Falk K, Rotzschke O, Wiesmuller KH, Jung G, Rammensee HG: Fine specificity of cytotoxic T lymphocytes primed in vivo either with virus or synthetic lipopeptide vaccine or primed in vitro with peptide. J Exp Med 174:1665, 1991
84. Bourgault I, Chirat F, Tartar A, Levy JP, Guillet JG, Venet A: Simian immunodeficiency virus as a model for vaccination against HIV. Induction in rhesus macaques of GAG-or NEF-specific cytotoxic T lymphocytes by lipopeptides. J Immunol 152:2530, 1994
85. Martinon F, Gras-Masse H, Boutillon C, Chirat F, Deprez B, Guillet JG, Gomard E, Tartar A, Levy JP: Immunization of mice with lipopeptides bypasses the prerequisite for adjuvant. Immune response of BALB/c mice to human immunodeficiency virus envelope glycoprotein. J Immunol 149:3416, 1992
86. Wiedemann F, Link R, Pumpe K, Jacobshagen U, Schaefer HE, Wiesmuller KH, Hummel RP, Jung G, Bessler W, Boltz T: Histopathological studies on the local reactions induced by complete Freund's adjuvant (CFA), bacterial lipopolysaccharide (LPS), and synthetic lipopeptide (P3C) conjugates. J Pathol 164:265, 1991
87. Bessler WG, Jung G: Synthetic lipopeptides as novel adjuvants. Res Immunol 143:548, 1992 (Discussion 143:579, 1992)
88. Reusser P, Riddell SR, Meyers JD, Greenberg PD: Cytotoxic T-lymphocyte response to cytomegalovirus after human allogeneic bone marrow transplantation: Pattern of recovery and correlation with cytomegalovirus infection and disease. Blood 78:1373, 1991
89. Quinnan GV Jr, Kirmani N, Rook AH, Manischewitz JF, Jackson L, Moreschi G, Santos GW, Saral R, Burns WH: Cytotoxic T cells in cytomegalovirus infection: HLA-restricted T-lymphocyte and non-T-lymphocyte cytotoxic responses correlate with recovery from cytomegalovirus infection in bone-marrow-transplant recipients. N Engl J Med 307:7, 1982
90. Meyers JD, Leszczynski J, Zaia JA, Flournoy N, Newton B, Snydman DR, Wright GG, Levin MJ, Thomas ED: Prevention of cytomegalovirus infection by cytomegalovirus immune globulin after marrow transplantation. Ann Intern Med 98:442, 1983
91. Schmidt GM, Kovacs A, Zaia JA, Horak DA, Blume KG, Nademanee AP, O'Donnell MR, Snyder DS, Forman SJ: Ganciclovir/immunoglobulin combination therapy for the treatment of human cytomegalovirus-associated interstitial pneumonia in bone marrow allograft recipients. Transplantation 46:905, 1988
92. Rook AH, Quinnan GV Jr, Frederick WJ, Manischewitz JF, Kirmani N, Dantzler T, Lee BB, Currier CB Jr: Importance of cytotoxic lymphocytes during cytomegalovirus infection in renal transplant recipients. Am J Med 76:385, 1984
93. Schmidt GM, Horak DA, Niland JC, Duncan SR, Forman SJ, Zaia JA: A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants; The City of Hope-Stanford-Syntex CMV Study Group [see comments]. N Engl J Med 324:1005, 1991
94. Meyers JD, Reed EC, Shepp DH, Thornquist M, Dandliker PS, Vicary CA, Flournoy N, Kirk LE, Kersey JH, Thomas ED, et al: Acyclovir for prevention of cytomegalovirus infection and disease after allogeneic marrow transplantation. N Engl J Med 318:70, 1988
95. Reusser P, Gambertoglio JG, Lilleby K, Meyers JD: Phase I-II trial of foscarnet for prevention of cytomegalovirus infection in autologous and allogeneic marrow transplant recipients [see comments]. J Infect Dis 166:473, 1992
96. Bowden RA, Digel J, Reed EC, Meyers JD: Immunosuppressive effects of ganciclovir on in vitro lymphocyte responses. J Infect Dis 156:899, 1987
97. Goodrich JM, Bowden RA, Fisher L, Keller C, Schoch G, Meyers JD: Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant. Ann Intern Med 118:173, 1993
98. Goodrich JM, Mon M, Gleaves CA, Du Mond C, Cays M, Ebeling DF, Buhles WC, DeArmond B, Meyers JD: Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation. N Engl J Med 325:1601, 1991
99. Lum LG: The kinetics of immune reconstitution after human marrow transplantation. Blood 69:369, 1987
100. Atkinson K: Reconstruction of the haemopoietic and immune systems after marrow transplantation. Bone Marrow Transplant 5:209, 1990
101. Saxon A, Mitsuyasu R, Stevens R, Champlin RE, Kimata H, Gale RP: Designed transfer of specific immune responses with bone marrow transplantation. J Clin Invest 78:959, 1986
102. Wimperis JZ, Brenner MK, Prentice HG, Reittie JE, Karayiannis P, Griffiths PD, Hoffbrand AV: Transfer of a functioning humoral immune system in transplantation of T-lymphocyte-depleted bone marrow. Lancet 1:339, 1986
103. Ljungman P, Fridell E, Lonnqvist B, Bolme P, Bottiger M, Gahrton G, Linde A, Ringden O, Wahren B: Efficacy and safety of vaccination of marrow transplant recipients with a live attenuated measles, mumps, and rubella vaccine. J Infect Dis 159:610, 1989
104. Kato S, Yabe H, Yabe M, Kimura M, Ito M, Tsuchida F, Tsuji K, Takahashi M: Studies on transfer of varicella-zoster-virus specific T-cell immunity from bone marrow donor to recipient. Blood 75:806, 1990
105. Boland GJ, Vlieger AM, Ververs C, De Gast GC: Evidence for transfer of cellular and humoral immunity to cytomegalovirus from donor to recipient in allogeneic bone marrow transplantation. Clin Exp Immunol 88:506, 1992
106. Kuzushima K, Yamamoto M, Kimura H, Ando Y, Kudo T, Tsuge I, Morishima T: Establishment of anti-Epstein-Barr virus (EBV) cellular immunity by adoptive transfer of virus-specific cytotoxic T lymphocytes from an HLA-matched sibling to a patient with severe chronic active EBV infection. Clin Exp Immunol 103:192, 1996
107. Kwak LW, Taub DD, Duffey PL, Bensinger WI, Bryant EM, Reynolds CW, Longo DL: Transfer of myeloma idiotype-specific immunity from an actively immunised marrow donor. Lancet 345:1016, 1995
108. Shouval D, Ilan Y: Transplantation of hepatitis B immune lymphocytes as means for adoptive transfer of immunity to hepatitis B virus. J Hepatol 23:98, 1995
109. Heslop HE, Ng CY, Li C, Smith CA, Loftin SK, Krance RA, Brenner MK, Rooney CM: Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nat Med 2:551, 1996
110. Meyers JD, Flournoy N, Thomas ED: Risk factors for cytomegalovirus infection after human marrow transplantation. J Infect Dis 153:478, 1986